PBYI Q4 2023 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+9.9% YoY

Gross Profit

$48M66.3% margin

Operating Income

$15M20.5% margin

Net Income

$12M17.0% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+28.6%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$231M

Total Liabilities

$177M

Stockholders' Equity

$53M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$66M	+9.9%
Gross Profit	$48M	$49M	-2.0%
Operating Income	$15M	$10M	+47.7%
Net Income	$12M	-$6M	+318.8%

Revenue Segments

Product

$53M74%

Royalty

$19M26%